120 related articles for article (PubMed ID: 23901848)
1. Acute antibody-mediated rejection in pediatric kidney transplants: a single center experience.
Twombley K; Thach L; Ribeiro A; Joseph C; Seikaly M
Pediatr Transplant; 2013 Nov; 17(7):E149-55. PubMed ID: 23901848
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
Nguyen S; Gallay B; Butani L
Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755
[TBL] [Abstract][Full Text] [Related]
3. Differential modulation of donor-specific antibodies after B-cell depleting therapies to cure chronic antibody mediated rejection.
Touzot M; Couvrat-Desvergnes G; Castagnet S; Cesbron A; Renaudin K; Cantarovich D; Giral M
Transplantation; 2015 Jan; 99(1):63-8. PubMed ID: 25029384
[TBL] [Abstract][Full Text] [Related]
4. Early Versus Late Acute Antibody-Mediated Rejection Among Renal Transplant Recipients in Terms of Response to Rituximab Therapy: A Single Center Experience.
Gheith O; Al-Otaibi T; Halim MA; Mahmoud T; Nair P; Monem MA; Al-Waheeb S; Hassan R; Nampoory N
Exp Clin Transplant; 2017 Feb; 15(Suppl 1):150-155. PubMed ID: 28260457
[TBL] [Abstract][Full Text] [Related]
5. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
6. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection.
Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N
Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274
[TBL] [Abstract][Full Text] [Related]
7. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib.
Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B
Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514
[TBL] [Abstract][Full Text] [Related]
8. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
[TBL] [Abstract][Full Text] [Related]
9. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of combination therapy for chronic antibody-mediated rejection in renal transplantation.
Kim MG; Kim YJ; Kwon HY; Park HC; Koo TY; Jeong JC; Jeon HJ; Han M; Ahn C; Yang J
Nephrology (Carlton); 2013 Dec; 18(12):820-6. PubMed ID: 24033843
[TBL] [Abstract][Full Text] [Related]
11. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
[TBL] [Abstract][Full Text] [Related]
12. Use of bortezomib for treatment of antibody medicated rejection in kidney transplant recipients--case report.
Hamawi K; Heilman RL; Mazur MJ; Chakkera HA; Mulligan DC; Moss AA; Mekeel KL; Reddy KS
Clin Transpl; 2009; ():407-14. PubMed ID: 20524306
[No Abstract] [Full Text] [Related]
13. Use of bortezomib to treat anti-HLA antibodies in renal transplant patients: a single-center experience.
Cicora F; Paz M; Mos F; Roberti J
Transpl Immunol; 2013 Dec; 29(1-4):7-10. PubMed ID: 23994721
[TBL] [Abstract][Full Text] [Related]
14. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
15. Effect of a proteasome inhibitor plus steroids on HLA antibodies in sensitized patients awaiting a renal transplant.
Aubert O; Suberbielle C; Gauthe R; Francois H; Obada EN; Durrbach A
Transplantation; 2014 May; 97(9):946-52. PubMed ID: 24759674
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib for the treatment of de novo HLA antibody-related antibody mediated rejection.
Al Meshari K
Clin Transpl; 2009; ():385-6. PubMed ID: 20524302
[No Abstract] [Full Text] [Related]
17. Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients.
Vo AA; Choi J; Cisneros K; Reinsmoen N; Haas M; Ge S; Toyoda M; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2014 Aug; 98(3):312-9. PubMed ID: 24770617
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: a case report.
Gazdic T; Svobodova E; Kubanek M; Kment M; Pagacova L; Viklicky O; Malek I; Kautzner J
Prog Transplant; 2015 Jun; 25(2):147-52. PubMed ID: 26107275
[TBL] [Abstract][Full Text] [Related]
19. The use of bortezomib as a rescue treatment for acute antibody-mediated rejection: report of three cases and review of literature.
Tzvetanov I; Spaggiari M; Joseph J; Jeon H; Thielke J; Oberholzer J; Benedetti E
Transplant Proc; 2012 Dec; 44(10):2971-5. PubMed ID: 23195008
[TBL] [Abstract][Full Text] [Related]
20. Differential outcomes in 3 types of acute antibody-mediated rejection.
Rafiq MA; de Boccardo G; Schröppel B; Bromberg JS; Sehgal V; Dinavahi R; Murphy B; Akalin E
Clin Transplant; 2009; 23(6):951-7. PubMed ID: 19624692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
